<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2400">
  <stage>Registered</stage>
  <submitdate>17/06/2009</submitdate>
  <approvaldate>17/06/2009</approvaldate>
  <nctid>NCT00924989</nctid>
  <trial_identification>
    <studytitle>A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma</scientifictitle>
    <utrn />
    <trialacronym>GALACCTIC</trialacronym>
    <secondaryid>2009-012820-97</secondaryid>
    <secondaryid>OSI-906-301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adrenocortical Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - OSI-906
Other interventions - Placebo

Experimental: Arm A: OSI-906 - 150 mg twice daily

Placebo Comparator: Arm B: Placebo - Matching placebo twice daily


Treatment: drugs: OSI-906
Administered orally

Other interventions: Placebo
Matching placebo administered orally

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival of single agent OSI-906 versus placebo - Time from date of randomization until time of documented death</outcome>
      <timepoint>33 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival - Time from randomization to disease progression based on RECIST version 1.1 or death due to any cause, whichever comes first</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate - Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD), based on RECIST criteria</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best overall response rate - Proportion of patients with a best overall response of CR or PR based on RECIST criteria</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response - Time from date of the first documented response (CP/PR) to documented progression or death due to underlying cancer</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to deterioration in Quality of Life - Measured by European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessed via physical exams, vital signs, laboratory assessments, electrocardiograms, and adverse events</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed adrenocortical carcinoma that is locally advanced or
             metastatic and not amenable to surgical resection.

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             (version 1.1).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &lt;= 2

          -  Predicted life expectancy &gt;= 12 weeks.

          -  At least 1 but no more than 2 prior drug regimens (including molecular targeted
             therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally
             advanced/metastatic ACC.

          -  A minimum of 3 weeks must have elapsed between the end of prior treatment and
             randomization.

          -  All patients must have received prior mitotane, either as neoadjuvant, adjuvant, or
             locally advanced/metastatic therapy.

          -  Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens
             or as systemic cytotoxic chemotherapy.

          -  Prior radiation therapy is permitted provided patients have recovered from the acute,
             toxic effects of radiotherapy prior to randomization.

          -  A minimum of 21 days must have elapsed between the end of radiotherapy and
             randomization.

          -  Prior surgery is permitted provided that adequate wound healing has occurred prior to
             randomization.

          -  Fasting glucose &lt; = 150 mg/dL (8.3 mmol/L).

          -  Adequate hematopoietic, hepatic, and renal function defined as follows: Neutrophil
             count &gt;= 1.5 x 10^9 /L;

          -  Platelet count &gt;= 100 x 10^9 /L;

          -  Bilirubin &lt;= 1.5 x Upper Limit of Normal (ULN);

          -  AST and ALT &lt;= 2.5 x ULN, or &lt;= 5 x ULN if patient has documented liver metastases or
             received prior mitotane therapy; and

          -  Serum creatinine &lt;= 1.5 x ULN or &lt;= 2.0 x ULN if the patient has received prior
             cisplatin.

          -  Patients, both males and females, with reproductive potential (ie, menopausal for less
             than 1 year and not surgically sterilized) must agree to practice effective
             contraceptive measures throughout the study.

          -  Women of childbearing potential must provide a negative pregnancy test (serum or
             urine) within 14 days prior to randomization.

          -  Patients must provide verbal and written informed consent to participate in the study.

          -  Radiologically-confirmed progressive disease within 6 months prior to randomization.

          -  Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if
             the dose has been stable for &gt;= 4 weeks at the time of randomization.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring
             insulinotropic or insulin therapy.

          -  Prior IGF-1R inhibitor therapy.

          -  Malignancy other than ACC within the past 3 years. Exceptions: resected basal cell or
             squamous cell carcinoma of the skin; cured in situ cervical carcinoma; cured ductal
             carcinoma in situ of the breast; and/or cured superficial bladder cancer.

          -  History of significant cardiovascular disease unless the disease is well-controlled.

          -  Significant cardiac diseases includes second/third degree heart block; clinically
             significant ischemic heart disease; mean QTcF interval &gt; 450 msec at screening;

          -  poorly controlled hypertension; congestive heart failure of New York Heart Association
             (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest,
             but ordinary physical activity results in fatigue, palpitation, or dyspnea).

          -  History of cerebrovascular accident (CVA) within 6 months prior to randomization or
             that resulted in ongoing neurologic instability.

          -  Use of drugs that have a risk of causing QT interval prolongation within 14 days prior
             to Day 1 dosing.

          -  Active infection or serious underlying medical condition (including any type of active
             seizure disorder within 12 months prior to randomization) that would impair the
             ability of the patient to receive study drug.

          -  History of any psychiatric condition that might impair the patient's ability to
             understand or to comply with the requirements of the study or to provide informed
             consent.

          -  Pregnant or breast-feeding females.

          -  Symptomatic brain metastases that are not stable, require steroids, are potentially
             life threatening, or that have required radiation within 28 days prior to
             randomization.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study drug.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>139</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal North Shore Hospital Department of Endocrinology - St Leonards</hospital>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gliwice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent
      OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who
      received at least 1 but no more than 2 prior drug regimens</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00924989</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Astellas Pharma Global Development</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>